Absolute effect of prostate cancer screening: Balance of benefits and harms by center within the European Randomized Study of prostate cancer screening

Clinical Cancer Research

Volumn 22, Issue 1, 2016, Pages 243-249

  Auvinen, Anssi ^a   Moss, Sue M ^b   Tammela, Teuvo L J ^c   Taari, Kimmo ^d   Roobol, Monique J ^e   Schröder, Fritz H ^e   Bangma, Chris H ^e   Carlsson, Sigrid ^f,g   Aus, Gunnar ^f   Zappa, Marco ^h   Puliti, Donella ^h   Denis, Louis J ⁱ   Nelen, Vera ⁱ   Kwiatkowski, Maciej ^j,k   Randazzo, Marco ^j,l   Paez, Alvaro ^m   Lujan, Marcos ⁿ   Hugosson, Jonas ^f  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

ⁱ Provinciaal Instituut voor Hygiene   (Belgium)

^j CANTONAL HOSPITAL AARAU   (Switzerland)

^k Academic Hospital Braunschweig   (Germany)

^l University Hospital Zudie rich   (Switzerland)

^m HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

ⁿ HOSPITAL INFANTA CRISTINA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; ANTIGEN DETECTION; ARTICLE; BELGIUM; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL PRACTICE; CORRELATION ANALYSIS; EUROPE; FINLAND; FOLLOW UP; HEALTH CARE FACILITY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NETHERLANDS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SPAIN; SWEDEN; SWITZERLAND; ADVERSE EFFECTS; AGED; BLOOD; EARLY CANCER DIAGNOSIS; HEALTH SURVEY; INCIDENCE; MASS SCREENING; MIDDLE AGED; MORTALITY; PROCEDURES; PROSTATIC NEOPLASMS;

AGED; BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; EUROPE; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MORTALITY; MULTICENTER STUDIES AS TOPIC; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84954566543     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0941     Document Type: Article

References (21)

1. Schröder FH, Hugosson J, Roobol MJ, Tammela T, Zappa M, Nelen V, et al. The European Randomized Study of Screening for Prostate Cancer - Mortality at 13 years of follow-up. Lancet 2014;384:2027-35.
2. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening. J Natl Cancer Inst 2009;101:374-83.
3. Etzioni R, Gulati R, Mallinger L, Mandelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Int Med 2013;58:831-8.
4. Heijnsdijk E, Wever E, Auvinen A, Hugoson J, Ciatto S, Nelen V, et al. Quality of life effects of prostate specific antigen screening. N Engl J Med 2012;367:595-605.
5. Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA 2002;287: 2813-4.
6. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Available from: www.consort-statement.org/consort- 2010. Accessed January 15, 2015.
7. Rembold CM. Number need to screen. BMJ 1998;317:307-12.
8. Richardson A. Screening and number needed to treat. J Med Screen 2001; 8:125-7.
9. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening. Ann Intern Med 2002;137:347-60.
10. de Koning HJ, Blom J, Merkelbach JW, Raaijmakers R, Verhaegen H, van Vliet P, et al. Determining the cause of death in randomised screening trial for prostate cancer. BJU Int 2003;92 Suppl 2:71-8.
11. Mäkinen T, Karhunen P, Aro J, Lahtela J, Määttänen L, Auvinen A. Cause of death attribution in a prostate cancer screening trial. Int J Cancer 2008;122:413-7.
12. Wu GH, Auvinen A, Määttänen L, Tammela T, Stenman UH, Hakama M, et al. Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. Int J Cancer 2012;131:1367-75.
13. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203-13.
14. Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al. Radical prostatectomy or watchful waiting in early prostate cancer.NEngl J Med 2014;370:932-42.
15. Bul M, Zhu X, Valdagnani R, Pickles T, Kakeni Y, Rannikko A, et al. Active surveillance for low-risk prostate cancer world-wide: the PRIAS study. Eur Urol 2013;63:597-603.
16. Schröder FH, Hugosson J, Roobol MJ, Tammela T, Ciatto S, Nelen V, et al. Prostate cancer mortality at 11 years of follow-up in the European Randomized study of Screening for Prostate Cancer (ERSPC). N Engl J Med 2012;366:981-90.
17. Heijnsdijk EAM, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst 2014;107:366.
18. Stephenson SK, Chang EK, Marks LS. Screening and detection advances of magnetic resonance image-guided prostate biopsy. Urol Clin North Am 2014;41:315-26.
19. Otto SJ, van Leeuwen PJ, Hoekstra JW, Merkelbach JW, Blom JHM, et al. Blinded and uniform causes of death verification in cancer screening. Eur J Cancer 2010;46:3061-67.
20. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002;94:167-73.
21. Saquib N, Saquib J, Ioannidis JP. Does screening for disease save lives in asymptomatic adults? Int J Epidemiol 2015;44:264-77.